A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
XMT-1107 has been shown in nonclinical studies to slow the growth of tumors. These effects
may result from blocking the growth of new blood vessels that help the tumors survive.